BR112023005715A2 - Vírus da diarreia epidêmica suína atenuado - Google Patents

Vírus da diarreia epidêmica suína atenuado

Info

Publication number
BR112023005715A2
BR112023005715A2 BR112023005715A BR112023005715A BR112023005715A2 BR 112023005715 A2 BR112023005715 A2 BR 112023005715A2 BR 112023005715 A BR112023005715 A BR 112023005715A BR 112023005715 A BR112023005715 A BR 112023005715A BR 112023005715 A2 BR112023005715 A2 BR 112023005715A2
Authority
BR
Brazil
Prior art keywords
epidemic diarrhea
diarrhea virus
swine epidemic
attenuated swine
virus
Prior art date
Application number
BR112023005715A
Other languages
English (en)
Inventor
Ruan Xiaosai
Liu Can
Li Haiyan
Yu Hongxin
Hou Yanhong
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112023005715A2 publication Critical patent/BR112023005715A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VÍRUS DA DIARREIA EPIDÊMICA SUÍNA ATENUADO. A presente invenção refere-se a uma proteína Spike C-terminal truncada de PEDV. Sequências de ácido nucleico incluindo a mesma e um vírus compreendendo a mesma, bem como métodos de uso também são fornecidos.
BR112023005715A 2020-09-29 2021-09-23 Vírus da diarreia epidêmica suína atenuado BR112023005715A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011048314.0A CN114315985A (zh) 2020-09-29 2020-09-29 减毒猪流行性腹泻病毒
PCT/US2021/051807 WO2022072215A2 (en) 2020-09-29 2021-09-23 Attenuated porcine epidemic diarrhea virus

Publications (1)

Publication Number Publication Date
BR112023005715A2 true BR112023005715A2 (pt) 2023-05-02

Family

ID=78372132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005715A BR112023005715A2 (pt) 2020-09-29 2021-09-23 Vírus da diarreia epidêmica suína atenuado

Country Status (15)

Country Link
EP (1) EP4221748A2 (pt)
JP (1) JP2023543033A (pt)
KR (1) KR20230079021A (pt)
CN (2) CN114315985A (pt)
AR (1) AR123646A1 (pt)
AU (1) AU2021353430A1 (pt)
BR (1) BR112023005715A2 (pt)
CA (1) CA3197074A1 (pt)
CL (1) CL2023000913A1 (pt)
CO (1) CO2023004100A2 (pt)
EC (1) ECSP23029637A (pt)
MX (1) MX2023003651A (pt)
PE (1) PE20240081A1 (pt)
TW (1) TW202221012A (pt)
WO (1) WO2022072215A2 (pt)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US3914408A (en) 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
EP0681026A1 (en) 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
EP0517751A4 (en) 1990-02-26 1993-03-31 Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
EP0587775A4 (en) 1991-06-06 1994-11-02 Medimmune Inc INDUCTION OF THE CTL RESPONSE BY FOREIGN ANTIGENS EXPRESSED IN MYCOBACTERIES.
CA2187768A1 (en) 1994-04-15 1995-10-26 Moser, Charlotte A. Aqueous solvent encapsulation method, apparatus and microcapsules
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
JP4619120B2 (ja) 2002-08-12 2011-01-26 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｔヘルパーエピトープおよびｂ細胞エピトープを含む新規な免疫原性リポペプチド
CA2494193A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
AU2003270779A1 (en) 2002-09-20 2004-04-08 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
KR20080013850A (ko) 2005-02-08 2008-02-13 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역원성 분자
WO2007127936A2 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods

Also Published As

Publication number Publication date
CN114315985A (zh) 2022-04-12
TW202221012A (zh) 2022-06-01
PE20240081A1 (es) 2024-01-16
KR20230079021A (ko) 2023-06-05
AU2021353430A1 (en) 2023-05-11
JP2023543033A (ja) 2023-10-12
WO2022072215A3 (en) 2022-07-07
CN116635521A (zh) 2023-08-22
WO2022072215A2 (en) 2022-04-07
AU2021353430A9 (en) 2024-01-18
EP4221748A2 (en) 2023-08-09
CL2023000913A1 (es) 2023-11-24
CN116635521A8 (zh) 2023-11-03
ECSP23029637A (es) 2023-07-31
CO2023004100A2 (es) 2023-04-05
MX2023003651A (es) 2023-04-19
CA3197074A1 (en) 2022-04-07
AR123646A1 (es) 2022-12-28

Similar Documents

Publication Publication Date Title
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
BR112018011711A2 (pt) peptídeos de direcionamento para direcionar virus adeno-associados (aav)
NI201600028A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
BR112022023591A2 (pt) Proteína spike (s) do coronavírus modificada e métodos de uso da mesma
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EA201170353A1 (ru) Антитела против гепатита с и их применение
UA108778C2 (xx) Протираковий злитий протеїн
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
EA201991065A1 (ru) Вакцина против свиного парвовируса
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
BR112015022780A2 (pt) reticuladores de produto químico
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
BR112023005715A2 (pt) Vírus da diarreia epidêmica suína atenuado
BR112018005464A2 (pt) expressão de proteínas contendo fc